In this issue of Blood, Ding et al demonstrated anti–programmed death 1 (anti–PD-1) responses that may benefit chronic lymphocytic leukemia (CLL) patients with Richter transformation (RT) but did not show… Click to show full abstract
In this issue of Blood, Ding et al demonstrated anti–programmed death 1 (anti–PD-1) responses that may benefit chronic lymphocytic leukemia (CLL) patients with Richter transformation (RT) but did not show activity in non-RT CLL patients.1
               
Click one of the above tabs to view related content.